Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s share price hit a new 52-week low on Friday . The company traded as low as C$0.89 and last traded at C$0.89, with a volume of 15062 shares. The stock had previously closed at C$0.93.
Medicenna Therapeutics Stock Up 9.4 %
The firm has a market cap of C$69.58 million, a price-to-earnings ratio of -2.56 and a beta of 1.21. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88. The firm has a fifty day moving average price of C$1.07 and a 200-day moving average price of C$1.56.
Insider Transactions at Medicenna Therapeutics
In other news, Senior Officer David Hyman purchased 20,000 shares of the company's stock in a transaction on Thursday, January 9th. The stock was bought at an average cost of C$1.45 per share, for a total transaction of C$29,000.00. Insiders own 22.57% of the company's stock.
Medicenna Therapeutics Company Profile
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Recommended Stories
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
